View
955
Download
0
Category
Preview:
DESCRIPTION
Practical management of the most common autoimmune bullous diseases
Citation preview
Practical Management of
the Most Common
Autoimmune
Bullous Diseases
By
Khalid M. Gharib
Corticosteroid is the most frequently used
agent in the treatment of Autoimmune
Bullous Diseases
CorticosteroidsCorticosteroids have anti-inflammatory and
immunosuppressive effects and their pharmacology is understood. It is important to monitor their various side effects,
both chronic and acute, which include adrenal insufficiency, electrolyte imbalances, hypertension, hyperglycemia, myopathy, immunosuppression, psychosis, cataracts, glaucoma, osteonecrosis and osteoporosis, infections, and gastrointestinal symptoms.
Actas Dermosifiliogr. 2008;99:441-55
Osteoporosis is monitored by :
yearly bone densitometry and controlled by administration of :
calcium(1,500 mg/d), vitamin D (400 IU/d), and bisphosphonates such as alendronate (Fosamax) (weekly tablets are available). ( selectively destroying macrophage and inhibiting their proinflammatory cytokines production).
The development of osteoporosis is related to the dose and the duration of therapy. It is estimated that in 30% to 50 % of patients on a long-term glucocorticoids regimen, fractures develop.
Actas Dermosifiliogr. 2008;99:441-55
The mechanism by which glucocorticoids cause osteoporosis is believed to be a combination of a decrease in calcium absorption and suppression of new bone formation by osteoblasts
Prednisolone in Pemphigus Vulgaris
The starting dose is 1 mg/kg/d divided into 2 or 3 doses.
( A POINT OF DISSCUSSION)
Most patients obtain remission within 4 to 12 weeks.
The dose is maintained for 6 to 10 weeks,
Then decreased by 10 to 20 mg every 2 to 4 weeks.
(J Am Acad Dermatol 2004;51:859-77.)
When the dose is 40 mg daily, the schedule is changed to every other day.
HOW?
This transition is accomplished by keeping the first day’s dose at 40 mg
and decreasing the second day’s dose by 5 to 10 mg every 2 to 4 weeks.
When the patient is taking 40 mg every other day,
the dose is tapered by 5 mg every 2 to 4 week.
(J Am Acad Dermatol 2004;51:859-77.)
If there is no recurrence, the patient undergoes a maintenance regimen of 5 mg daily or every other day for several years.
( A POINT OF DISSCUSSION).
The administration of methylprednisolone, 1 g/d intravenously over 1 to 3 hours for a few (usually 3) consecutive days, is referred to as pulse steroid therapy
(J Am Acad Dermatol 2004;51:859-77.)
In Bullous PemphegoidThe dose is 1/2 to 3/4 mg/kg/d.Unlike the treatment of PV, higher doses of prednisone
are rarely needed. A clinical response is usually obtained within 1 to 4
weeks and is indicated by healing of existing lesions and cessation of new blister formation.
The prednisone dose is then gradually decreased by relatively large portions (10 mg) initially and smaller portions (2.5-5 mg) later.
(J Am Acad Dermatol 2004;51:859-77.)
When the daily dose is 30 to 40 mg, a shift to every other day is attempted to decrease the potential for long-term glucocorticoid side effects.
This shift is usually accomplished with a decrease in the second-day dose by 5 to 10 mg every 1 to 2 weeks.
Once the second day dose is nil, the first-day dose may be tapered slowly.
There are NO clear criteria regarding cure or remission.Some authors define them on the basis of indirect or
direct immunofluorescence, Others on the basis of symptoms or the requirement for
immunosuppressive therapy. One of the criteria used is the absence of lesions
for 3 months, but this is inconsistent with clinical experience with
these patients. (J Am Acad Dermatol 2004;51:859-77.)
Imuran)) AzathioprineThe most common steroid-sparing immunosuppressive
drug is azathioprine at a dose of 50 mg every 12 hours,The usual dose of azathioprine is 2.5 mg/kg/dBut it is best to adjust the dose according to the thiopurine
methytransferase enzyme that metabolizes the drug. Thiopurine methyltransferase deficiency (approximately 1
in 300 individuals). Patients with a high level of thiopurine methyltransferase may need 4 to 5 mg/ kg/d.
Actas Dermosifiliogr. 2008;99:441-55
Treatment With Intravenous Cyclophosphamide(Genoxal)
1. Begin with oral cyclophosphamide at 50 mg every 12 hours and monitor tolerance by laboratory analysis
(suspend treatment if a white cell count < 2500 cells/mm3
is observed)
2. Intravenous treatment
a. Dose every 15-30 days
b. 1-1.5 g/m2; infusion in 200 mL over 2 hours
c. Hydration with saline (500 mL in 3 hours)
d. Cycles, 3 to 10 according to response3. Follow-up with complete blood count, urinalysis,
and monitoring of nausea/vomiting and infections Actas Dermosifiliogr. 2008;99:441-55
Dexamethasone-Cyclophosphamide Pulse Therapy
Phase 1:
Dexamethasone (100 mg dissolved in 500ml 5% dextrose) slow intravenous over 2h on 3consecutive days
+ cyclophosphamide 500 mg on day 1
DCP repeated every 4 w
Between these pulses : once daily oral cyclophosphamide 50 mg
Phase 2: Monthly pulse therapy of DCP for minimum
6 mPhase 3: stop monthly pulses but continue oral 50
mg for additional one yearPhase 4: withdrawn oral and follow up .
Dermatology online journal,2003
Oral cyclophosphamide for treatment ofpemphigus vulgaris and foliaceus
Patients received oral cyclophosphamide at a dose of 2 to 2.5 mg/kg/d each morning followed by aggressive oral hydration (hemorrhagic cystitis)with at least 2 to 3 L of fluids.
Prednisone (1 mg/kg/d) was also used, and tapering of the prednisone commenced after 2 to 3 months of therapy. Reductions of prednisone then occurred on a monthly basis, until a maintenance dose was achieved.
Patients with severe cutaneous disease (more than 40% body surface involvement), Once prednisone was reduced below 20 mg/d, the cyclophosphamide dose was adjusted to maintain an absolute neutrophil count of 1500 to 2500 c/L
If the absolute neutrophil count decreased below this target range, the cyclophosphamide was temporarily discontinued and restarted at a lower dose.
American academy of dermatology,2003
Azathioprine is less effective than cyclophosphamide
but appears to be more widely used.
It is less toxic and therefore requires less monitoring than cyclophosphamide.
Due to its relatively lower toxicity, lower risk of sterility, and lower lifetime risk of malignancy, it is indicated in younger persons.
Treatment With Rituximab (Mabthera)1. Prior to treatment Hepatitis C virus
serology Antibodies (indirect immunofluorescence,
enzyme- linked immunosorbent assay).
2. Dose, 375 mg/m2 (600-650 mg) a. One day a week b. Four weeks
c. Some use intravenous immunoglobulin 0.4 g/kg the day before (infection prophylaxis)
d. In case of relapse, a single dose according to clinical course
3. Premedicate with 1 ampule of dexchlorpheniramine and 1 g intravenous paracetamol 1 hour before
4. Slow infusion (6 hours) beginning at 15 mL/min for 15 minutes
Actas Dermosifiliogr. 2008;99:441-55
Autoimmune bullous skin disorder intensity score
The severity of pemphigus can vary even within
individuals.
Efforts have been made to develop a scale for the measurement of severity similar to the Psoriasis
Area Severity Index,6 covering criteria such as : the rule of 9’s, the extent of erosion or dry
crust, and tolerated foods (the so-called autoimmune bullous skin
disorder intensity score), with good intentions but little practical use.
Severity is also classified as mild, moderate, and severe
according to the judgment of the observer. The disease continues to be associated with a
mortality of 5%, usually as a result of treatment complications.
(J Am Acad Dermatol 2004;51:859-77.)
The choice of therapy is dependent to some degree on the severity of the disease at presentation.
Other factors that play a role in choosing therapy are patient-related (age, general health, and associated medical illnesses such as diabetes, hypertension, or tuberculosis) and drug-related (onset of action, efficacy, adverse effects, and cost).
Unless there is an absolute contraindication, the initial therapy of PV is systemic glucocorticoid.
(J Am Acad Dermatol 2004;51:859-77.)
(J Am Acad Dermatol 2004;51:859-77.)
(J Am Acad Dermatol 2004;51:859-77.)
(J Am Acad Dermatol 2004;51:859-77.)
Recommended